ВАНГ Дженни В. (US),ВУДВАРД Дэвид Ф. (US),НИ Мин (US),МАРТОС Джоуз Л. (GB),КАРЛИНГ Уильям Р. (GB)
申请号：
RU2013104268/15
公开号：
RU2013104268A
申请日:
2011.07.01
申请国别(地区):
RU
年份:
2014
代理人:
摘要：
1. A method of treating inflammation in a patient in need thereof, comprising administering to the patient an effective amount of a compound of the formula: wherein R is H or lower alkyl, R1 is a hydrocarbon radical or substituted hydrocarbon radical, and the dashed line is a saturated or unsaturated bond, or a double bond, wherein said formula further includes prodrugs, isomers and pharmaceutically acceptable salts thereof. 2. The method of claim 1, wherein the compound is: .3. The method according to claim 2, including reducing the secretion of ENA-78 in a patient. The method according to claim 2, including reducing the secretion of IL-8 in a patient. The method according to claim 2, including reducing the secretion of MCP-1 in a patient. The method according to claim 2, including reducing the secretion of PAI-1 in a patient. The method according to claim 2, including reducing the secretion of CD-40 in a patient. The method according to claim 2, comprising reducing the secretion of G-C-SF in the patient. The method of claim 2, comprising reducing the secretion of GM-CSF in a patient. The method according to claim 2, including reducing the secretion of IL-1α in a patient. The method according to claim 2, including reducing the secretion of IL-18 in a patient. The method of claim 2, comprising reducing the secretion of MDC in a patient. The method of claim 2, comprising reducing RANTES secretion in a patient. The method of claim 2, wherein the compound is at least as effective as coxibs (cyclooxygenase-2 inhibitors) and NSAIDs (non-steroidal anti-inflammatory drugs) in treating inflammation in a patient in need of such treatment without causing side effects cardiovascular system, kidney and / or gastrointestinal tract. 15. A method of reducing the secretion of a cytokine selected from the group consisting of ENA-78, IL-8, MCP-1, PAI-1, TNFα, CD-40, G-CSF, G1. Способ лечения воспаления у пациента, нуждающегося в этом, включающий введение пациенту эффективного количес
